

# Aaron M Drucker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5931433/publications.pdf>

Version: 2024-02-01

53  
papers

1,509  
citations

516710

16  
h-index

330143

37  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2147  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. <i>Journal of Investigative Dermatology</i> , 2017, 137, 26-30.	0.7	444
2	Drug-Induced Photosensitivity. <i>Drug Safety</i> , 2011, 34, 821-837.	3.2	147
3	Research Techniques Made Simple: Assessing Risk of Bias in Systematic Reviews. <i>Journal of Investigative Dermatology</i> , 2016, 136, e109-e114.	0.7	133
4	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.5	127
5	Facial and neck erythema associated with dupilumab treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1339-1347.	1.2	63
6	Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 358-370.	5.7	56
7	Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project. <i>British Journal of Dermatology</i> , 2017, 177, 1043-1051.	1.5	50
8	Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1342-1348.	3.8	43
9	Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 347-354.	2.5	34
10	Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. <i>European Journal of Haematology</i> , 2013, 90, 142-150.	2.2	34
11	The multidimensional burden of atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 603-606.	1.0	32
12	Vincristine and Corticosteroids as First-Line Treatment of Kasabach-Merritt Syndrome in Kaposiform Hemangioendothelioma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 155-159.	1.2	31
13	Patient Burden of Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2017, 35, 303-316.	1.7	31
14	Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1191-1200.	1.9	24
15	Network meta-analyses of systemic treatments for psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2019, 180, 282-288.	1.5	19
16	Quality of reporting in systematic reviews published in dermatology journals. <i>British Journal of Dermatology</i> , 2020, 182, 1469-1476.	1.5	18
17	Gluten intake and risk of psoriasis, psoriatic arthritis, and atopic dermatitis among United States women. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 661-665.	1.2	18
18	Teaching Dermatology to Internal Medicine Residents: Needs Assessment Survey and Possible Directions. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 39-45.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. <i>American Journal of Dermatopathology</i> , 2015, 37, 523-529.	0.6	17
20	A case of familial paraganglioma syndrome type 4 caused by a mutation in the SDHB gene. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 702-706.	2.8	12
21	Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study. <i>Lupus</i> , 2016, 25, 376-381.	1.6	12
22	Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. <i>BMJ Open</i> , 2018, 8, e023061.	1.9	12
23	Atopic dermatitis and bone health: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 615-628.	2.4	12
24	Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 546-554.	1.2	11
25	Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1682-1690.	1.2	11
26	Diagnosis validation and clinical characterization of atopic dermatitis in Nurses' Health Study 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 588-594.	2.4	10
27	Association between psoriasis and risk of dementia: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 790-792.	1.2	10
28	Narrowband UVB as an effective substitute for psoralen plus UVA: lessons from a psoralen shortage. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 267-268.	1.5	9
29	Core outcome set implementation supported by the <i>BJD</i> . <i>British Journal of Dermatology</i> , 2021, 184, 987-989.	1.5	9
30	Atopic dermatitis and cardiovascular disease: What are the clinical implications?. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1736-1738.	2.9	8
31	Smoking and risk of adult-onset atopic dermatitis in US women. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 561-563.	1.2	8
32	Eczema and subsequent suicide: a matched case-control study. <i>BMJ Open</i> , 2018, 8, e023776.	1.9	7
33	Tralokinumab for atopic dermatitis: a promising new therapy. <i>British Journal of Dermatology</i> , 2021, 184, 386-387.	1.5	7
34	Revisiting atopic dermatitis and cardiovascular disease. <i>British Journal of Dermatology</i> , 2018, 179, 801-802.	1.5	5
35	Hot Stuff: Thermal Imaging Aids in Cellulitis Diagnosis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 482-484.	0.7	4
36	Treatments for primary squamous cell carcinoma and squamous cell carcinoma in situ of the skin: A systematic review and network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 479-482.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Insight into the patient experience of eczema through a crowdsourcing approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 861-863.	3.8	3
38	Atopic dermatitis and cardiovascular disease: have we seen enough to refute a causal link?. <i>British Journal of Dermatology</i> , 2018, 178, 1235-1236.	1.5	3
39	Depression and anxiety in atopic dermatitis: increasing recognition and opportunities to intervene. <i>British Journal of Dermatology</i> , 2019, 181, 442-443.	1.5	3
40	Accuracy of Algorithms to Identify People with Atopic Dermatitis in Ontario Routinely Collected Health Databases. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1840-1843.	0.7	3
41	Reporting of randomized controlled trial abstracts in dermatology journals according to CONSORT guidelines. <i>British Journal of Dermatology</i> , 2021, 185, 673-675.	1.5	2
42	Taking steps to improve the assessment and management of rosacea. <i>British Journal of Dermatology</i> , 2017, 176, 283-284.	1.5	1
43	Understanding common but understudied diseases in dermatology. <i>British Journal of Dermatology</i> , 2018, 178, 22-23.	1.5	1
44	Is baricitinib up next for atopic dermatitis?. <i>British Journal of Dermatology</i> , 2020, 183, 199-200.	1.5	1
45	The need for comparative effectiveness data to guide management of acne vulgaris. <i>British Journal of Dermatology</i> , 2021, 185, 476-477.	1.5	1
46	Bruton tyrosine kinase inhibition warrants further study for pemphigus. <i>British Journal of Dermatology</i> , 2021, 185, 691-692.	1.5	1
47	Noninferiority Randomized Controlled Trials. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1773-1777.	0.7	1
48	Treating moderate-to-severe atopic dermatitis: what do dermatologists do with limited evidence?. <i>British Journal of Dermatology</i> , 2017, 176, 1441-1442.	1.5	0
49	Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality-of-life measure for adult atopic dermatitis. <i>British Journal of Dermatology</i> , 2018, 178, 1211-1212.	1.5	0
50	Pilot study of the CAPS (Clinical extent, Area, Pruritus, Sleep) measure for atopic dermatitis severity. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 380-381.e4.	1.0	0
51	Widening the tightrope: new abstract guidelines for BJD authors. <i>British Journal of Dermatology</i> , 2021, 185, 687-688.	1.5	0
52	Characterization of discontinuation and nonpublication of phase 3 randomized clinical trials for psoriasis. <i>British Journal of Dermatology</i> , 2022, , .	1.5	0
53	Systemic treatments for psoriasis: not another network meta-analysis!. <i>British Journal of Dermatology</i> , 2022, , .	1.5	0